Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Measuring calcium intake can help to identify osteoporosis in men with prostate cancer

10.04.2007
Measuring a man’s daily calcium intake is an effective way of identifying prostate cancer patients with a higher than average risk of osteoporosis, according to the April issue of the urology journal BJU International.

Researchers from the Autonoma University School of Medicine, Barcelona, Spain, looked at a cross-section of 372 men with prostate cancer. 72 per cent were receiving androgen-deprivation therapy (ADT) and 28 per cent had undergone a radical prostatectomy. Their average age was just under 70.

They found that 49 per cent of the men had osteoporosis, including 55 per cent of those who had received the ADT hormone therapy and 35 per cent of those who had had a prostatectomy.

These figures are considerably higher than the prevalence of osteoporosis in the general male population, where it’s estimated that about 20 per cent of all male osteoporosis cases occur in the 61 to 70 age group.

A dietary questionnaire revealed that only seven per cent of the men were consuming more than 1000 mg of calcium a day - the average daily calcium intake was 610mg in men with osteoporosis and 683mg in those without.

These levels are well below the 1000mg recommended for all 25-65 year-olds by the US National Institutes of Health and the 1500mg recommended for men over 65.

“Our research showed a significant relationship between a low daily calcium intake and higher levels of osteoporosis in men with prostate cancer” says lead researcher Dr Jacques Planas from the University’s Department of Urology.

“Men who had undergone ADT hormone therapy were particularly at risk and longer treatment and increased age were also related to higher levels of osteoporosis.

“What was particularly interesting was the fact that more than a third of the patients who hadn’t received hormone treatment also developed osteoporosis.”

Osteoporosis is caused by loss of bone mineral density, which makes bones brittle and significantly more likely to fracture. It is more common in older people and has been strongly linked to hormonal changes, such as the female menopause.

Links to ADT hormone therapy have also been reported, but the Barcelona study is thought to be the first to look at using daily calcium as a diagnostic tool to identify prostate cancer patients who face an increased risk of osteoporosis, including those who have not received ADT.

“Men account for about a third of all hip fractures, but they are much more likely to die after an injury of this nature than women, so it is important to identify possible risks at an early stage” adds Dr Planas.

Hormone treatment ranged from 12 to 98 months, with an average of just over 42 months. Men with bone disorders or secondary causes of osteoporosis were excluded from the study.

As well as the dietary questionnaire, the men taking part in the study had their bone mineral density measured at the lumbar spine and four different hip sites in line with the guidelines developed by the International Society for Clinical Densitometry for the diagnosis of osteoporosis.

“We carried out our research to discover whether there was a relationship between low daily calcium intake and reduced bone mineral density, which there clearly was” say Dr Planas.

“We also wanted to know if daily calcium intake could be used as a prognostic factor for osteoporosis, especially for patients receiving ADT. Our research suggests that it does provide a good pointer to whether a prostate cancer patient also has osteoporosis.”

The authors suggest that patients with prostate cancer should be routinely advised to take at least 1000mg of calcium a day and that their bone mineral density should be assessed, particularly before starting ADT, and monitored at regular intervals after the treatment begins.

Annette Whibley | alfa
Further information:
http://bjui.org
http://www.blackwellpublishing.com

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>